Literature DB >> 17712177

YKL-40 protein expression in the early developing human musculoskeletal system.

Julia S Johansen1, Poul E Høyer, Lars A Larsen, Paul A Price, Kjeld Møllgård.   

Abstract

YKL-40 is a growth factor for chondrocytes and fibroblasts. The aim was to evaluate YKL-40 expression in the musculoskeletal system during early human development. We studied sections from 15 human embryos [weeks 5.5-8; 7- to 31-mm crown-rump length (CRL)] and 68 fetuses (weeks 9-14; 33- to 105-mm CRL) for YKL-40 protein expression by immunohistochemistry. YKL-40 mRNA expression was evaluated in two human embryos (days 41 and 51). Initially YKL-40 is expressed in all germ layers: ecto-, meso-, and endoderm. YKL-40 mRNA and protein expression are found in tissues of the ecto-, meso-, and endoderm, and YKL-40 protein expression is present during development of cartilage, bone, joints, and muscles. At the cellular level, YKL-40 protein expression is high in tissues characterized by rapid proliferation, marked differentiation, and undergoing morphogenetic changes. Examples of rapid cell proliferation include the chondrogenic inner layer of perichondrium and the osteogenic inner layer of periosteum. Differences in YKL-40 expression during differentiation are found in the chondrogenic and osteogenic cell lineages. The initial shaping of cartilage and bone models and joints is concomitant with a strong outline of YKL-40-positive cells. This indicates that YKL-40 is associated with cell proliferation, differentiation, and tissue morphogenesis during development of the human musculoskeletal system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712177     DOI: 10.1369/jhc.7A7245.2007

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  30 in total

1.  YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers.

Authors:  Christian B Brøchner; Julia S Johansen; Lars A Larsen; Mads Bak; Hanne B Mikkelsen; Anne Grete Byskov; Claus Yding Andersen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2011-12-01       Impact factor: 2.479

Review 2.  New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma.

Authors:  Daniel Elieh Ali Komi; Tohid Kazemi; Anton Pieter Bussink
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

3.  Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression.

Authors:  Hong Peng; Qiang Su; Zhong-Chao Lin; Xiu-Hua Zhu; Ming-Sha Peng; Zhen-Bing Lv
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

4.  Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.

Authors:  Camilla Bjørnbak; Christian B Brøchner; Lars A Larsen; Julia S Johansen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2014-03-04       Impact factor: 2.479

5.  Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages.

Authors:  Michelino Di Rosa; Giulia Malaguarnera; Corinne De Gregorio; Filippo Drago; Lucia Malaguarnera
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

6.  Chitinase 3-Like-1-Deficient Splenocytes Deteriorated the Pathogenesis of Acute Graft-Versus-Host Disease via Regulating Differentiation of Tfh Cells.

Authors:  Zengyao Li; Hao Lu; Jian Gu; Jing Liu; Qin Zhu; Yunjie Lu; Xuehao Wang
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

7.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

8.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

9.  YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Authors:  Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen
Journal:  BMC Cancer       Date:  2009-01-09       Impact factor: 4.430

Review 10.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.